These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7949207)

  • 1. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
    Dowsett M; Coombes RC
    Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
    MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
    Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
    Lønning PE; Dowsett M; Jones A; Ekse D; Jacobs S; McNeil F; Johannessen DC; Powles TJ
    Breast Cancer Res Treat; 1992; 23(1-2):57-62. PubMed ID: 1446052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
    Geisler J; Johannessen DC; Anker G; Lønning PE
    Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
    Dowsett M; Stein RC; Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
    Coombes RC; Hughes SW; Dowsett M
    Eur J Cancer; 1992; 28A(12):1941-5. PubMed ID: 1419285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
    Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
    Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors and their use in the sequential setting.
    Coombes RC; Harper-Wynne C; Dowsett M
    Endocr Relat Cancer; 1999 Jun; 6(2):259-63. PubMed ID: 10731118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
    Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
    Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
    MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
    Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
    Dowsett M
    Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
    Coombes RC; Goss P; Dowsett M; Gazet JC; Brodie A
    Lancet; 1984 Dec; 2(8414):1237-9. PubMed ID: 6150277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation aromatase inhibitors.
    Bajetta E; Zilembo N; Noberasco C
    Tumori; 1995; 81(2):77-80. PubMed ID: 7778222
    [No Abstract]   [Full Text] [Related]  

  • 17. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
    Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
    Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
    Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC
    Eur J Cancer; 1992; 28(2-3):415-20. PubMed ID: 1591054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and their use in the adjuvant setting.
    Coombes RC
    Recent Results Cancer Res; 1998; 152():277-84. PubMed ID: 9928565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
    Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC
    Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.